SkinBioTherapeutics Plc
SBTX.L
SBTX.LSkinBioTherapeutics Plc
London Stock Exchange24.15
GBp
+0.90
(+3.87%)
ISIN
GB00BF33H870
CUSIP
G7208A105
Return %
Stock
S&P500
1Y
106.91
10.92
3Y
-50.66
26.22
5Y
291.48
120.31
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mr. Stuart John Ashman
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The Core Newcastle upon Tyne United Kingdom NE4 5TF
- IPO Date
- Apr 5, 2017
- Website
- skinbiotherapeutics.com
- Similar Companies
- Business
- SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.